Pharmaceutical composition comprising refined Indigo naturalis extracts and the use thereof

Patent metadata

Field	Value
Publication number	US-10555985-B2
Application number	US-201916261773-A
Country	US
Kind code	B2
Filing date	Jan 30, 2019
Priority date	Apr 9, 2015
Publication date	Feb 11, 2020
Grant date	Feb 11, 2020

Abstract

A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

First claim

The invention claimed is:

1. A method of treating a disease or condition selected from the group consisting of psoriasis, an inflammatory skin condition, onychomycosis, skin cancer, abnormal keratinization induced disease, skin aging, and pustular dermatosis, comprising administering to a subject in need thereof a pharmaceutical composition comprising a solid extract of Indigo Naturalis, wherein the solid extract comprises, relative to the total weight of the extract:
65% to 90% (w/w) indirubin;
0.1-15% (w/w) indigo; and
0.01-5% (w/w) tryptanthrin,
wherein the pharmaceutical composition comprises 0.002% to 0.077% (w/w) of the solid extract relative to the total weight of the pharmaceutical composition.

2. The method of claim 1 , wherein the solid extract comprises 0.1-5% (w/w) tryptanthrin relative to the total weight of the extract.

3. The method of claim 2 , wherein the solid extract further comprises 0.1-5% (w/w) qingdainone relative to the total weight of the extract.

4. The pharmaceutical composition of claim 1 , wherein the solid extract is micronized and comprises particles having a particle size of less than or equal to 30 μm in 99% of the particles.

5. The method of claim 1 , wherein the pharmaceutical composition is orally administered.

6. The method of claim 1 , wherein the pharmaceutical composition is topically administered.

7. The method of claim 1 , wherein the disease or condition is psoriasis, onychomycosis, skin aging, or pustular dermatosis.

8. The method of claim 1 , wherein the disease or condition is the inflammatory skin condition selected from the group consisting of atopic dermatitis (AD), eczema, and superinfected skin.

9. The method of claim 1 , wherein the disease or condition is the skin aging selected from skin rejuvenation, tissue regeneration for scars and skin senescence.

10. The method of claim 1 , wherein the disease or condition is the pustular dermatosis selected from acne, ichthyosis, and palmoplantar keratoderma.

11. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

12. The method of claim 11 , wherein the pharmaceutical carrier comprises at least one of an oil, an emulsifier, a thickening agent, and a preservative.

Assignees

• Galderma Sa

Inventors

• Chantalat Laurent
• Andres Philippe

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/10

  Antimycotics · CPC title

• A61P17/12

  Keratolytics, e.g. wart or anti-corn preparations · CPC title

• A61P17/10

  Anti-acne agents · CPC title